Abstract: The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, improved cellular uptake, stability under both acidic (pH<4) and basic (pH>7) conditions, reduced immunogenicity, and improved globotriaosylceramide removal from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.

Abstract: Aspects of the present invention relate to a head-worn computer having a see-through computer display, a frame mechanically adapted to hold the see-through computer, a first side arm pivotally attached to the frame and adapted to hold the head-worn computer in place on a head of the user, wherein the first side arm comprises a temple section and an ear horn section and the temple section further comprising a compartment adapted to contain a battery, wherein the battery powers the see-through computer display.

Abstract: Aspects of the present invention relate to a head-worn computer having a see-through computer display, a frame mechanically adapted to hold the see-through computer, a first side arm pivotally attached to the frame and adapted to hold the head-worn computer in place on a head of the user, wherein the first side arm comprises a temple section and an ear horn section and the temple section further comprising a compartment adapted to contain a battery, wherein the battery powers the see-through computer display.

Abstract: The present disclosure provides engineered acid alpha-glucosidase polypeptides, recombinant polynucleotides encoding the engineered acid alpha-glucosidase polypeptides, and method of using the engineered acid alpha-glucosidase polypeptides and the recombinant polynucleotides for therapeutic purposes.

Abstract: Engineered lipase polypeptides have been optimized to provide improved thermostability, protease stability, and stability under a range of pH conditions, including acidic (pH<7) and basic (pH>7) conditions. Compositions containing the engineered lipase polypeptides can be used for therapeutic and/or nutritional purposes. Polynucleotides encoding the engineered lipase polypeptides are also provided, as well as methods for making the engineered polynucleotides and lipase polypeptides.

Abstract: The present invention provides engineered acid alpha-glucosidase (GAA) polypeptides and compositions thereof. In some embodiments, the engineered GAA polypeptides have been optimized to provide increased expression, stability at neutral pH, and activity in cell lysates. The invention also provides methods for utilization of the compositions comprising the engineered GAA polypeptides for therapeutic and other purposes.

Abstract: A method includes predicting, before a first period of time, a plurality of predicted event metric values and value ranges corresponding to a first plurality of events to occur over the first period of time based on a plurality of prediction models, determining an actual event metric value of the first plurality of events, and determining a plurality of model range multi-partition error (MRME) values indicative of an accuracy, precision, and relative range of the forecasting models based on the actual event metric values, value ranges, and the predicted event metric values. The method includes selecting one of the forecasting models based on the MRME values, determining a cyber security control limit based on a predicted event metric value or predicted event metric range by the selected forecasting model, and outputting an alert based on an actual event metric value being outside of the cyber security control limit.

Abstract: The present invention provides engineered lipase polypeptides and compositions thereof. The engineered lipase polypeptides have been optimized to provide improved thermostability, protease stability, and stability under a range of pH conditions, including acidic (pH<7) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered lipase polypeptides for therapeutic and/or nutritional purposes. The present invention also provides polynucleotides encoding the engineered lipase polypeptides, as well as methods for making the engineered polynucleotides and lipase polypeptides.

Abstract: The present invention provides engineered acid alpha-glucosidase (GAA) polypeptides and compositions thereof. In some embodiments, the engineered GAA polypeptides have been optimized to provide increased expression, stability at neutral pH, and activity in cell lysates. The invention also provides methods for utilization of the compositions comprising the engineered GAA polypeptides for therapeutic and other purposes.

Abstract: An extracorporeal bone compressing link and apparatus and method using same. Active devices that incorporate the extracorporeal bone compressing link can transport and compress bone through external means by acting on conventional bone fasteners including but not limited pins or wires that penetrate through the skin and fixate into bone.

Abstract: Aspects of the present invention relate to a head-worn computer having a see-through computer display, a frame mechanically adapted to hold the see-through computer, a first side arm pivotally attached to the frame and adapted to hold the head-worn computer in place on a head of the user, wherein the first side arm comprises a temple section and an ear horn section and the temple section further comprising a compartment adapted to contain a battery, wherein the battery powers the see-through computer display.

Abstract: A method includes predicting, before a first period of time, a plurality of predicted event metric values and value ranges corresponding to a first plurality of events to occur over the first period of time based on a plurality of prediction models, determining an actual event metric value of the first plurality of events, and determining a plurality of model range multi-partition error (MRME) values indicative of an accuracy, precision, and relative range of the forecasting models based on the actual event metric values, value ranges, and the predicted event metric values. The method includes selecting one of the forecasting models based on the MRME values, determining a cyber security control limit based on a predicted event metric value or predicted event metric range by the selected forecasting model, and outputting an alert based on an actual event metric value being outside of the cyber security control limit.

Abstract: Aspects of the present invention relate to a head-worn computer having a see-through computer display, a frame mechanically adapted to hold the see-through computer, a first side arm pivotally attached to the frame and adapted to hold the head-worn computer in place on a head of the user, wherein the first side arm comprises a temple section and an ear horn section and the temple section further comprising a compartment adapted to contain a battery, wherein the battery powers the see-through computer display.

Abstract: The present invention provides engineered phenylalanine ammonia lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia lyase (PAL) polypeptides. In some embodiments, the engineered PAL polypeptides are optimized to provide enhanced catalytic activity, as well as reduced sensitivity to proteolysis and increased tolerance to storage at elevated temperatures. In some embodiments, the engineered PAL polypeptides contain fewer phenylalanine residues than wild-type PAL polypeptides. The present invention also provides methods for the use of the compositions comprising the engineered PAL polypeptides for therapeutic and industrial purposes.

Abstract: The present invention provides engineered phenylalanine ammonia lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia lyase (PAL) polypeptides. In some embodiments, the engineered PAL polypeptides are optimized to provide enhanced catalytic activity, as well as reduced sensitivity to proteolysis and increased tolerance to storage at elevated temperatures. In some embodiments, the engineered PAL polypeptides contain fewer phenylalanine residues than wild-type PAL polypeptides. The present invention also provides methods for the use of the compositions comprising the engineered PAL polypeptides for therapeutic and industrial purposes.

Abstract: A new shape changing staple and instrument for the fixation of structures to include bone tissue and industrial materials. This new staple stores elastic mechanical energy to exert force on fixated structures to enhance their security and in bone affect its healing response. This staple once placed changes shape in response to geometric changes in the materials structure, including healing bone tissue. The staple is advanced over prior staples due to its: 1) method of operation, 2) high strength, 3) method of insertion, 4) compressive force temperature independence, 5) energy storing staple retention and delivery system, 6) compatibility with reusable or single use product configuration, 7) efficient and cost effective manufacturing methods, and 8) reduction in the steps required to place the device. In addition to the staple's industrial application an embodiment for use in the fixation of the musculoskeletal system is shown with staple, cartridge, and extrusion handle.

Abstract: An extracorporeal bone compressing link and apparatus and method using same. Active devices that incorporate the extracorporeal bone compressing link can transport and compress bone through external means by acting on conventional bone fasteners including but not limited bone fasteners including but not limited to screws, pins or wires that penetrate through the skin and fixate into bone.

Abstract: Aspects of the present invention relate to a head-worn computer having a see-through computer display, a frame mechanically adapted to hold the see-through computer, a first side arm pivotally attached to the frame and adapted to hold the head-worn computer in place on a head of the user, wherein the first side arm comprises a temple section and an ear horn section and the temple section further comprising a compartment adapted to contain a battery, wherein the battery powers the see-through computer display.

Abstract: The present invention provides engineered tyrosine ammonia-lyase (TAL) polypeptides and compositions thereof. In some embodiments, the engineered TAL polypeptides have been optimized to provide enhanced catalytic activity and enhanced acid stability, while reducing sensitivity to proteolysis and increasing tolerance to acidic pH levels. The invention also provides methods for utilization of the compositions comprising the engineered TAL polypeptides for therapeutic and industrial purposes.

Abstract: Described is a new bone healing method and class of bone fixation implants that change shape once implanted so as to minimize non-healing and speed the bone healing process. The bone fixation method involves shape changing implants that continuously hold the bones in apposition so that a gap does not form. Gaps in time allow non-bony tissue to infiltrate and stop healing. Furthermore, the implants actively compress bone to increase bone mass and strength. Bone cell pressure due to compression and electrical current flow due to bone deformation act to stimulate healing. The new implant designs also provide a scaffolding to conduct bone through the implant and across the healing bone interface. The methods and designs are applicable to but not limited to use for bone screws, plates, staples, rods, cylinders and external fixation devices.